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Objective. Death ligand FasL, its agonistic receptor Fas, tumor necrosis factor related apoptosis inducing
ligand (TRAIL) and its agonistic death receptors DR4 and DR5 are implied in carcinogenesis, tumor immune
surveillance and response to chemotherapy. TRAIL receptor agonists are evaluated as anti-cancer agents. This
study aimed to relate expression of death ligands/receptors and downstream initiator caspase 8 and its anti-
apoptotic homologue FLICE like inhibitory protein (c-FLIP) in ovarian cancers to chemotherapy response and
survival.
Methods. Fas, FasL, TRAIL, DR4, DR5, caspase 8 and c-FLIP were determined immunohistochemically on a
tissue microarray containing 382 ovarian cancers. Protein expression proﬁles were correlated with
clinicopathologic variables, chemotherapy response and survival.
Results. Most tumors expressed DR4, DR5, caspase 8 and c-FLIP. High c-FLIP expression was associated
with expression of caspase 8 and both TRAIL receptors. TRAIL and Fas were associated with low tumor grade
and better progression-free survival (HR 0.63, p=.018 and HR 0.54, p=.012), respectively, and Fas with
disease-speciﬁc survival (HR 0.49, p=0.009) in univariate analysis.
Conclusions. Fas and TRAIL loss is associated with dedifferentiation and worse prognosis. Expression of
DR4, DR5, caspase 8 and c-FLIP by most ovarian cancers does not correlate with survival. High c-FLIP
expression should be taken into account for death receptor targeted therapies.© 2009 Elsevier Inc. All rights reserved.Introduction
Ovarian cancer is the ﬁfth most common cause of cancer deaths in
women [1]. Late stage disease at diagnosis and acquired resistance to
chemotherapy are characteristic for the course of most ovarian
cancers. These characteristics exemplify the complexity of ovarian
carcinogenesis, of which a deﬁned sequence of progression has not yet
been established [2]. The resulting heterogeneity among ovarian
cancers and consequently in factors underlying clinical response
complicates the deﬁnition of prognostic and predictive factors for
individualized treatment. Distinctive for all cancers is deregulation of
the apoptotic machinery [3]. Apoptosis can be induced through two
pathways. In the intrinsic pathway, diverse cellular stressors cause
sensors within the cell to promote cytochrome c release from the
mitochondria, resulting in the formation of the apoptosome and
activation of caspase 3, which sets the ﬁnal execution phase of
apoptosis inmotion. The extrinsic apoptotic pathway is activated upon
binding of death ligands from the tumor necrosis factor (TNF) family to
their cognate receptors at the cell surface. The death ligands TNFVries).
ll rights reserved.related apoptosis inducing ligand (TRAIL) and Fas ligand (FasL/CD95L)
are members of the TNF family [4]. TRAIL can bind ﬁve receptors of
which death receptor 4 (DR4) and death receptor 5 (DR5) transmit an
apoptotic signal [5]. FasL binds to one agonistic receptor, Fas (CD95),
and one soluble antagonistic receptor, DcR3 [6]. Trimerization of the
receptors upon ligand binding causes formation of a death inducing
signaling complex (DISC) in which the initiator caspase 8 is activated.
Active caspase 8 cleaves various designated cellular proteins including
pro-caspase 3, resulting in apoptosis [4]. An important regulator of
caspase 8 activation is its anti-apoptotic homologue c-FLIP, which is
up-regulated in many tumor types and involved in resistance to
chemotherapy and death receptor induced apoptosis [7].
Sensitivity of cancer cells to death ligand induced apoptosis has
resulted in development of death receptor targeted drugs as anti-
cancer agents. Because systemic administration of Fas targeted agents
caused severe hepatotoxicity in mice [8,9], only therapies directed at
local administration are now investigated [10]. The recombinant
human (rh) form of TRAIL and agonistic antibodies targeting DR4 and
DR5 show efﬁcacy in numerous tumor cell lines, including ovarian
cancer cell lines and in various xenograft tumor models in mice,
without side effects [11]. These results have led to clinical studies
which showed that these agents are well tolerated [12-14].
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receptor and Fas activation, assessing expression of key proteins of the
extrinsic pathway in ovarian cancer is of interest. Alterations in the
expression of FasL, TRAIL, its receptors [15,16], caspase 8 [15,17] and
c-FLIP [7] have been implied in carcinogenesis andmay hamper future
therapies directed at death receptors. Furthermore, because response
to chemotherapeutic drugs can be mediated through death ligand
dependent and independent activation of caspase 8, these alterations
may cause resistance to chemotherapy [18-20]. Robust co-expression
data of proteins involved in the extrinsic pathway may deﬁne
occurrence of these alterations in tumors and their impact on
prognosis. Furthermore, they may assist in patient selection for future
therapies targeting the extrinsic pathway.
Therefore, the aim of this study was to evaluate protein expression
of Fas, FasL, TRAIL, DR4, DR5, caspase 8 and c-FLIP on a tissue
microarray (TMA) containing tumor tissue of 382 ovarian cancer
patients and to correlate these expression proﬁles with clinicopath-
ological characteristics and disease outcome.
Materials and methods
Patients
From ovarian cancer patients treated since 1985 at the University
Medical Center Groningen or afﬁliated hospitals all clinical, patho-
logical and follow-up data have prospectively been stored in a
database. Tumor samples from 382 patients were collected on a TMA.
Patients with borderline or non-epithelial tumors were excluded.
Primary treatment for all patients consisted of surgery and 90% of the
patients eligible for systemic treatment received platin-based regi-
mens as described previously [21]. Primary tumor samples obtained at
surgery before any systemic treatment was administered were
available for 359 patients. When residual tumor mass was present,
response to chemotherapy was determined after three or six cycles
based on World Health Organization criteria. Intervention surgery
was performed after three chemotherapy cycles and second look
surgery after six when indicated. Follow-up lasted up to 10 years. All
relevant data were ﬁled in a separate anonymous database in which
patients were given unique codes to protect patient identity. Database
management was restricted to two people with access to the larger
database containing all patients' characteristics. Due to these
procedures no additional patient or institutional review board
approval was required according to Dutch Law.
TMA construction
TMAs were constructed as described previously [21]. Representa-
tive tumor tissue samples were selected from hematoxylin and eosin
stained slides. Four 0.6-mm cores were punched from each donor
block and put into 12 recipient parafﬁn TMA blocks. Each array
contained 240 tissue cores, representing 55 tumor samples in
quadruplicate and 10 internal controls in duplicate (composed of
ﬁve tumor, one benign and four non-tumor samples). From each block
4-µm sections were cut andmounted on aminopropyltriethoxysilane-
treated slides.
Antibodies
The TMAs were stained with polyclonal goat anti-TRAIL (1:100,
clone K-18, Santa Cruz Biotechnology, Santa Cruz, CA), polyclonal
goat anti-DR4 (1:100, clone C20, Santa Cruz Biotechnology),
polyclonal rabbit anti-DR5 (1:100, clone PC392, Calbiochem, San
Diego, CA), monoclonal mouse anti-Fas (1:50, clone CH-11, Upstate
Biotechnology, Temecula, CA), polyclonal rabbit anti-FasL (1:100,
clone N-20, Santa Cruz Biotechnology), monoclonal mouse anti-
caspase 8 (1:100, clone 1C12, Cell Signaling Technology, Danvers,MA) and monoclonal mouse anti-c-FLIP, detecting both FLIPL and
FLIPS (1:10, clone NF6, Alexis, Lausanne, Switzerland).
Immunohistochemistry
Staining procedures for all antibodies were performed as described
previously [22-25]. After deparafﬁnization in xylene and re-hydration
in ethanol, antigen retrieval was performed by incubation in citrate
buffer at 96 °C for DR5 and FasL or high pressure cooking for c-FLIP
and caspase 8. Endogenous peroxidase activity was blocked with 3%
hydrogen peroxide in all slides except those for Fas detection. Avidin/
biotin blocking solutions (Vector Laboratories, Burlingame, UK) were
applied for DR4, DR5 and TRAIL. Prior to primary antibody incubation,
slides were pre-incubated with 1% human AB serum (DR4, DR5 and
FasL) or normal rabbit serum (TRAIL). Primary antibody incubation
for c-FLIP was overnight; other antibodies were applied for 1 h. c-FLIP
staining was detected by incubation with EnVison (DAKO, Glostrup,
Denmark), caspase 8 staining with rabbit anti-mouse peroxidase
antibody (DAKO), followed by goat anti-rabbit peroxidase antibody
(DAKO) and for all other stainings with appropriate biotinylated
secondary antibodies and peroxidase-labeled streptavidin (DAKO).
Peroxidase activity was visualized with diaminobenzidine. Slides
were counterstained with hematoxylin.
Normal tissue (kidney for FasL, liver for Fas) and tumor sections
found positive on previous occasions served as positive control for Fas,
FasL, DR4, DR5 and TRAIL staining. Negative controls were obtained by
omission of the primary antibody, and by incubation with normal
isotype controls. For caspase 8 and c-FLIP controls were used as
described previously [24].
All sections were simultaneously reviewed by two observers
(E.W.D. and W.B.-v.E.), without knowledge of the clinical data.
Independent scoring was performed prior to simultaneous evaluation
with agreement of N90% for all stainings. Discordant cases and ﬁnal
scoring were reviewed with a gynecological pathologist (H.H.) and
assigned on consensus of opinion. Cores containing b10% tumor tissue
and all cases with b2 cores were excluded from ﬁnal analysis. Staining
intensity was estimated and scored semi-quantitatively in four classes
for DR4, DR5 and caspase 8 as negative (0), moderate (1), positive (2)
and strong positive (3). Staining for Fas, FasL, TRAIL and c-FLIP was
scored in three classes as negative (0), moderate (1) and positive (2).
If heterogeneous staining intensity occurred between four cores of the
same tumor, the highest staining intensity was chosen for ﬁnal
scoring if the core with highest staining contained N50% tumor tissue.
For statistical analysis all classes were initially studied separately and
then dichotomized. For DR4, DR5 and caspase 8, categories 2 and 3
were considered positive and 1 and 0 as negative. For TRAIL, FasL and
Fas, 2 was considered positive and 1 and 0 as negative. For c-FLIP
staining 2 and 1 were considered positive and 1 as negative [24].
Statistical analysis
Statistical analysis was performed with SPSS 14.0 for Windows
(SPSS, Inc., Chicago, IL). Comparisons between categorical variables
were made with χ2 tests or Fisher exact tests where appropriate.
Comparisons between unpaired tumor samples obtained before and
after chemotherapy were made using Mann–Whitney U tests. To
exclude the possibility of a type I error in these multiple comparisons,
p values b0.01 were considered statistically signiﬁcant. Response to
chemotherapy was analyzed using logistic regression analysis for
patients with a residual tumor mass ≥2 cm receiving platinum-based
chemotherapy (n= 141). Differences in progression-free survival
and disease-speciﬁc survival were analyzed with two-sided log-rank
testing and Cox proportional hazards analysis. p values b0.05 were
considered signiﬁcant. Progression-free and disease-speciﬁc survival
were deﬁned, respectively, as time from primary surgery until date of
progression or relapse and as time from primary surgery until death
Table 1
Clinicopathological characteristics of the patients (n= 382).
n %
FIGO stage
Stage I 73 19.1%
Stage II 36 9.4%
Stage III 223 58.4%





Clear cell 48 12.6%
Endometriod 20 5.2%
Adenocarcinoma NOS 19 5.0%
Other 23 6.0%
Tumor grade
Grade I 68 17.8%
Grade II 90 23.6%




b2 cm 183 47.9%
≥2 cm 173 45.3%
Missing 26 6.8%
Type of chemotherapy
No chemotherapy 55 14.4%
Platinum monotherapy 164 42.9%
Platinum/taxane containing 119 31.2%
Other regimen 40 10.5%
Missing 4 1.0%






551E.W. Duiker et al. / Gynecologic Oncology 116 (2010) 549–555due to ovarian cancer. For multivariate analysis, age at diagnosis (b58
years (median), ≥58 years), FIGO stage (I/II (early), III/IV (late)),
tumor type (serous, non-serous), tumor grade (grade I/II, grade
III/undifferentiated) and residual tumor size after primary surgery
(b2 cm, ≥2 cm) were used as covariates.Table 2
Staining results and clinicopathological characteristics.















Early stage 70/98 (71.4) 0.58 88/93 (94.6) 0.78 73/93 (78.5) 0.70 81/9




















Grade I/II 97/137 (70.8) 0.36 131/137
(95.6)

























p values are derived from χ2 analysis.Results
Patient characteristics
Clinicopathological data are summarized in Table 1. Median
follow-up time was 29.3 months (range 0–213); one patient was
lost to follow-up. Three hundred seventy-six patients (98.4%)
received primary surgery, whereas 6 patients (1.6%) received
chemotherapy prior to debulking surgery. Debulking surgery with a
residual tumor mass of b2 cm was achieved in 75 (30.5%) late stage
patients. Three hundred twenty-three (84.6%) patients received ﬁrst
line chemotherapy, of whom 173 (49.0%) received it as adjuvant
therapy with no evidence of residual tumor. In 55 patients no
chemotherapy was administered because of stage Ia disease (34
patients, 9%), ineligibility or patient refusal. At the time of data
analysis, 22 (20.4%) early and 184 (68.1%) late stage patients had died
of ovarian cancer, 3 (2.8%) early and 38 (14.1%) late stage patients
were alive with disease and the other patients were alive without
evidence of disease. Median progression-free survival was 49.6 (range
0–207) months for early and 11.5 (range 0–149) months for late stage
patients. Median disease-speciﬁc survival was 57.6 (range 0–207)
months and 19.7 (range 0–213) months for early and late stage
patients, respectively.
Associations of proteins with clinicopathological characteristics
Staining results were obtained in 92.8–94.7% of primary tumors
available (n=359) (Table 2). Staining for all proteins was cytoplas-
mic, with no apparent membranous staining (Fig. 1).
Most tumors expressed DR5, DR4, caspase 8 and c-FLIP (Table 2).
Combining data of 322 tumors with expression results on both DRs
showed that 70.8% of tumors expressed both death receptors, 26.7%
expressed one receptor and only 2.5% expressed neither DR4 nor DR5.
Positive c-FLIP expression was associated with higher differentiation
grade (p=0.049). TRAIL, Fas and FasL were less frequently expressed.
TRAIL expression was more frequent in tumors of low grade
(p=0.006) and reduced in late stage tumors (p=0.01). FasL and
Fas expression occurred more often in low grade tumors (p=0.03
and pb0.001, respectively) and were associated with a smaller











































































Fig. 1. Results of immunostaining for TRAIL, DR4, DR5, caspase 8, c-FLIP, FasL and Fas. N stands for negative and P for positive staining (magniﬁcation ×10).
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separately, TRAIL was not associated with grade, while late stage
tumors of low grade expressed FasL and Fas more frequently
(p=0.02 and p=0.001, respectively). After adjustment for multiple
testing, only the associations of TRAIL and Fas with low grade tumors
sustained.
Associations between proteins
Comparison of protein expression proﬁles of biological relevance
revealed several associated proﬁles (Supplementary Table 1A and B).In early stage tumors, DR5 was positively associated with caspase
8 staining (p=0.008). In late stage tumors, DR4 staining correlated
with positive FLIP staining (p=0.001) and negative TRAIL staining
(p=0.007). Strikingly, 75.7% of the tumors expressing both DRs also
expressed c-FLIP, while tumors with reduced expression of at least
one DR were more often associated with negative c-FLIP expression
(60.5%) (pb0.0001) (Fig. 2). These associations were also observed for
early (p=0.004) and late stage tumors (p=0.001) separately.
Caspase 8 staining was positively correlated with c-FLIP (p=0.008)
in late stage tumors. Finally, in late stage tumors negative Fas
expressionwas associatedwith negative FasL staining (p=0.008). For
Fig. 2. Death receptor expression in relation to c-FLIP expression in early and late stage
ovarian tumors.
553E.W. Duiker et al. / Gynecologic Oncology 116 (2010) 549–555188 patients data on p53 stainingwere available [21]. No relationships
were identiﬁed between the protein expression of the proteins under
study and p53.
Protein expression in pre- and post-chemotherapy tumor samples
Comparison of staining patterns in paired tumor samples (n= 43)
revealed no alterations in protein expression proﬁles after chemo-
therapy. When primary tumor samples were compared with all
post-chemotherapy samples available, Fas expression was reduced
in post-chemotherapy samples (p=0.048).
Response to chemotherapy and survival in relation to protein staining
To assess the presence of a correlation between expression of the
proteins under study and response to chemotherapy, univariate
regression analysis was performed in 141 patients with a residual
tumor mass≥2 cm after initial surgery, who received platinum-based
chemotherapy. Expression proﬁles were not correlated with response
to chemotherapy.
Positive TRAIL expression was associated with a better progression-
free survival in log-rank tests and univariate Cox proportional
hazard analysis (HR 0.63, 95% CI 0.42–0.92, p=0.018) (Supplementary
Table 2). However, this association was not found when the data were
analyzed separately in early and late stages (Fig. 3). Positive Fas staining
was associated with better progression-free and disease-speciﬁc
survival (p=0.012 and p=0.008, respectively) (Figs. 4A and B),
which was also observed in Cox proportional hazard analyses (HR
0.54, 95% CI 0.33–0.88, p=0.012 and HR 0.49, 95% CI 0.28–0.84
p=0.009, respectively). In subgroup analysis Fas was not associated
with survival in early and late stage tumors.Fig. 3. Progression-free survival according to TRAIL expressionIn multivariate analysis only advanced stage and a residual tumor
≥2 cm after primary surgery were independent predictors of poor
progression-free survival (HR 3.92, 95% CI 2.17–7.084, pb0.0001 and
HR 1.94, 95% CI 1.33–2.83, p=0.001, respectively) and disease-
speciﬁc survival (HR 3.3, 95% CI 1.73–6.29, pb0.0001 and HR 2.11, 95%
CI 1.41–3.16, pb0.0001, respectively).
Discussion
In the largest study to date analyzing the protein expression of the
death ligands TRAIL, FasL, their cognate agonistic receptors, caspase
8 and c-FLIP in ovarian cancers, we showed that the majority of
cancers expressed at least one death receptor, as well as caspase 8 and
its anti-apoptotic homologue c-FLIP. Moreover, these data show that
derangement of the Fas/FasL system, which is implied in malignant
transformation of the ovaries [26] is indeed the case in human ovarian
cancer. In addition, ovarian tumors that have retained Fas expression
are better differentiated and have a better progression-free and
disease-speciﬁc survival, which support data showing that loss of Fas
expression is implied in dedifferentiation and acquisition of a higher
malignant potential in several cancers [27-29]. Previous studies
examining protein expression of Fas, FasL or both in ovarian cancers
showed substantial variation which can be explained by small sample
sizes, inclusion of tumors classiﬁed as benign, borderline and
malignant and different use of antibodies and scoring systems
[23,30-32]. Moreover, in agreement with a previous study [33] we
used cut-off values for deﬁnition of positive or negative staining based
on dichotomization of staining classes according to their association
with prognosis.
FasL expression is commonly reported to increase with malignant
progression and tumor grade, which was not observed in our study
[29,32]. In addition, FasL expression was not associated with a worse
prognosis and is therefore not supportive for the tumor counterattack
hypothesis [34] in ovarian cancers.
TRAIL expression was associated with lower tumor grade and
better progression-free survival when all tumors were analyzed. In
previous studies in ovarian cancers TRAIL was also associated with
low tumor grade [35] and early stage [22,35], but not with prognosis
[22,35,36]. Among colon adenomas and carcinomas loss of TRAIL
expression occurred in a subset of colon carcinomas [37] and in
samples spanning oral cancer progression it was an early event in
carcinogenesis [38]. These results suggest that loss of TRAIL
expression represents a survival advantage for tumor cells, possibly
because they evade apoptosis induction by para- or autocrine released
TRAIL. This is supported by a study which showed that in response to
interferon-gamma Ewing tumor cells produce and secrete functional
TRAIL that induces apoptosis in unstimulated Ewing tumor cells [39].
The majority of tumors in our study expressed DR4, DR5, caspase
8 and c-FLIP. A striking ﬁnding was the association of c-FLIPin all patients and early and late stage tumors separately.
Fig. 4. (A) Progression-free survival according to Fas expression in all patients and early and late stage tumors separately. (B) Disease-speciﬁc survival according to Fas expression in
all patients and early and late stage tumors separately.
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which suggests that apoptotic death receptor signaling is counteracted
in ovarian cancers. These associations were, however, not correlated
with prognosis, nor were the individual proteins. Up-regulation of the
anti-apoptotic caspase 8 homologue c-FLIP was reported in several
tumor types [7] and was associated with a poor clinical outcome in
Burkitt lymphomas [40] and bladder urothelial carcinomas [41]. In
vitro, c-FLIP induces resistance to Fas and TRAIL receptor targeted
drugs in vitro [42-45] and is therefore a target for modulating death
receptor induced apoptosis. In colon cancer patients, high DR4
expression was an independent prognostic factor for worse disease-
free andoverall survival [46]. HighDR5 expressionwas associatedwith
decreased survival in univariate analysis in ovarian cancers [35] and
was independently associated with decreased survival in breast and
small lung cancers [47,48]. These different results underline the
complexity of death receptor signaling,which is not only dependent on
expression of its constituents, but also on external factors and the
intracellular apoptotic machinery and might therefore be tissue
speciﬁc. Moreover, it becomes increasingly evident that single
prognostic factors, e.g., HER2 and hormone receptors in breast and c-
kit in GIST tumors, are rather an exception than the rule. Considering
the redundancy of signaling pathways, it is not surprising that in most
tumors numerous factors are likely to inﬂuence prognosis [49].
Furthermore, although alterations in the death receptor pathway are
involved in chemoresistance [19,50,51], the main tumoricidal mech-
anism of most conventional drugs is not likely to act through the
extrinsic pathway. Therefore, our results show that in ovarian cancers
loss of TRAIL and Fas expression represents an important aspect in
dedifferentiation and escape from tumor immune surveillance. In
addition, deregulation of the extrinsic pathway by c-FLIP expression
occurs, but these changes are not of critical signiﬁcance for disease
outcome. They may, however, be of signiﬁcance for future therapies
targeting the extrinsic pathway. Clinical studies with rhTRAIL,agonistic antibodies directed at DR4 or DR5 and Fas are ongoing.
Membranous DR expression on tumors is a pre-requisite for these
drugs to be effective as anti-cancer agents, but functionality of the
downstream signaling pathway is of equal importance. Therefore, it
needs to be established whether these protein expression proﬁles
correlate with functionality of the death receptor pathway in ovarian
cancers, which can be achieved by relating clinical responses to TRAIL
receptor agonists with tumor characteristics.
Resistance to death receptor targeted agents and to conventional
chemotherapies can be overcome by combining these drugs. Many
different mechanisms were described to be involved in this synergy,
including down-regulation of c-FLIP [52]. Consequently, combinations
of conventional chemotherapeutics and death receptor drugs warrant
further development as novel strategies for cancer treatment.
In conclusion, loss of Fas and TRAIL is associated with dedifferen-
tiation and a worse prognosis in ovarian cancers. Expression of anti-
apoptotic c-FLIP is associated with caspase 8 and death receptor
expression, which should be considered for future death receptor
targeted therapies in ovarian cancer.
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